Press release
Geron to Present at the H.C. Wainwright Global Investment Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.\n\nA webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.\n\nAbout Geron\n\nGeron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220517005151/en/\n\nAron Feingold\nInvestor and Media Relations\[email protected]\[email protected]\n\nSource: Geron Corporation","length":2549,"tagName":"div"}]